A Study to Assess Point of Care Platelet Function


About this study

The purpose of this study is to compare Placor outputs between two groups (Group 1, healthy donors and Group 2, not acutely ill donors reporting daily clopidogrel use).  20 heathy donors and 20 patients maintained on clopidogrel therapy (half on clopidogrel alone and half on both aspirin and clopidogrel therapy) will be enrolled.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • For 20 healthy controls, individuals without a history of easy bruising/bleeding who have not consumed aspirin-containing prescription or over-the-counter medications or prescription anti-platelet agents for 10 days prior to study enrollment. 
  • For the 20 volunteers in the anti-platelet agent group, 20 non-acutely ill volunteers or patients who have taken either clopidogrel alone (10 volunteers) or both aspirin and clopidogrel (any doses) for the 10 consecutive days prior to study enrollment.

Exclusion Criteria: 

  • History of easy bruising/bleeding.
  • Taking over-the-counter or prescription aspirin or anti-platelet medication (group 1).
  • Not taking either clopidogrel alone or the combination of aspirin and clopidogrel for each of the prior 10 days (group 2). 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Bradley Karon, M.D., Ph.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer